Brief: Heartbeam Says Received NSE Letter From FDA For 12-Lead ECG Synthesis Software - SEC Filing
21/11/2025 16:44
Nov 21 (Reuters) - Heartbeam Inc BEAT.O: HEARTBEAM INC - RECEIVES NSE LETTER FROM FDA FOR 12-LEAD ECG SYNTHESIS SOFTWARE - SEC FILING HEARTBEAM INC - EVALUATING LAUNCH OF FDA-CLEARED 3D ECG SYSTEM - SEC FILING HEARTBEAM INC - TO WORK WITH FDA TO RESOLVE NSE ISSUE - SEC FILING Source text: [ID:n0001213900-25-113353] Further company coverage: BEAT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Heartbeam
See all newsBrief: Heartbeam Announces Strategic Shift To Accelerate Global Adoption Of Its Ambulatory ECG Signal Platform And Leadership Transition
Brief: Heartbeam Reports First Quarter 2026 Results
HeartBeam Q1 net loss narrows as commercialization advances
Brief: Heartbeam Initiates Pilot Study Of First On-Demand 12-Lead ECG Patch To Detect Ischemia Outside The Clinic
Brief: Heartbeam Expands Commercial Presence Across Four Key U.S. Markets With Addition Of Premier Concierge Practice